Incyte (MEX:INCY) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
82 GF Score
Price MXN2,067.00
GF Value MXN1,795.60
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte FFO per Share?

FFO per Share only applies to REITs.

MEX:INCY
82GF Score
Incyte Corp MEX:INCY
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,067.00 is trading 15.1% above its estimated GF Value™ of MXN1,795.60. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • FFO per Share:
  • GF Value™: MXN1,795.60 vs. price of MXN2,067.00 (15.1% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
82GF Score

Get the complete analysis for MEX:INCY

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,067.00
Price
MXN1,795.60
GF Value